Skip to main content

InflaRx N.V.

IFRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001708688

No open-market purchases or sales by InflaRx N.V. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $211.6M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding InflaRx N.V. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of IFRX: Q4 2021 compared with Q1 2022
MeasureQ4 2021Of which not filed for Q1 2022Q1 2022Change
Holders38132−5
Shares9.27M2006.45M−2.83M (−30.5%)
Value$44.1M$1.00K$12.0M−$32.1M (−72.8%)

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held InflaRx N.V. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to IFRX in Q1 2022
InstitutionSharesValue% of portfolio
Bank of Montreal241,000$603.0K0.00%
Marshall Wace, LLP34,353$63.0K0.00%
Virtu Financial LLC28,909$53.0K0.00%
Citigroup Inc6,805$13.0K0.00%

Sold out (9)

Institutions that held InflaRx N.V. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of IFRX in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Sofinnova Investments, Inc.1,161,736$5.53M
OrbiMed Advisors LLC875,297$4.17M
Walleye Capital LLC530,432$2.52M
Bank Julius Baer & Co. Ltd, Zurich197,607$941.0K
Gyon Technologies Capital Management, LP100,706$479.0K
Kingsview Wealth Management, LLC71,870$342.0K
Susquehanna International Group, LLP27,414$130.0K
Cutler Group LP2,800$13.0K
Tower Research Capital LLC (TRC)231$1.00K

Not filed for Q1 2022 yet (1)

Institutions that held InflaRx N.V. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IFRX in Q4 2021 that haven't filed for Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Harbour Investments, Inc.200$1.00K